XML 47 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Summary of Significant Accounting Policies (Details)
 12 Months Ended
Dec. 30, 2022
USD ($)
product
segment
country
Dec. 31, 2021
USD ($)
Jan. 01, 2021
USD ($)
Organization And Summary Of Significant Policies [Line Items]      
Number of countries with FDA approval, excluding the U.S. | country 62    
Number of operating segments | segment 1    
Impairment charge on goodwill | $ $ 0 $ 0 $ 0
Percent discount for prompt payment 2.00%    
Discount expected to be earned 100.00%    
Medicare Part D funding mandate     70.00%
Cost of goods sold is related to product 3.00%    
Advertising expense | $ $ 41,600,000 $ 31,800,000 $ 25,100,000
Maximum      
Organization And Summary Of Significant Policies [Line Items]      
Estimated useful lives 15 years    
Resulting From Discovery Efforts      
Organization And Summary Of Significant Policies [Line Items]      
Number of products that entered in the commercial marketplace | product 4    
Products Derived From Other Compounds      
Organization And Summary Of Significant Policies [Line Items]      
Number of products that entered in the commercial marketplace | product 2